Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping Imatinib first-line in chronic phase CML Patients.
Fiche publication
Date publication
juillet 2019
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GUERCI-BRESLER Agnès, Dr LAROSA Fabrice
Tous les auteurs :
Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Réa D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX
Lien Pubmed
Résumé
TKI discontinuation is an emerging goal in CML management and several studies demonstrated the feasibility of stopping safely imatinib. A sustained DMR on long-term TKI is critical prior to attempting treatment-free remission (TFR). Results reported recently, failed to identify robust and reproducible predictive factors for the selection of the best candidates for successful TFR.
Référence
Clin. Cancer Res.. 2019 Jul 10;: